Treatment of tall stature in boys with somatostatin analogue 201–995: effect on final height

Noordam, C.; Daalen, S.T. van; Otten, Barto J.

doi:10.1530/eje.1.02087

Cited by 19 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Somatostatin analogs have shown to cause a modest height reduction. One promising study with long-acting lanreotide demonstrated a mean height reduction of 3.8 cm; however, this treatment is still considered experimental (97,98). Pegvisomant, a GH receptor antagonist, has not yet been studied as a growth reduction treatment in patients with tall stature without GH excess.…”

Section: Treatmentmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Diagnostic and therapeutic approach of tall stature

Albuquerque

Scalco

Jorge

2017

European Journal of Endocrinology

View full text Add to dashboard Cite

Tall stature is defined as a height of more than 2 standard deviations (s.d.) above average for same sex and age. Tall individuals are usually referred to endocrinologists so that hormonal disorders leading to abnormal growth are excluded. However, the majority of these patients have familial tall stature or constitutional advance of growth (generally associated with obesity), both of which are diagnoses of exclusion. It is necessary to have familiarity with a large number of rarer overgrowth syndromes, especially because some of them may have severe complications such as aortic aneurysm, thromboembolism and tumor predisposition and demand-specific follow-up approaches. Additionally, endocrine disorders associated with tall stature have specific treatments and for this reason their recognition is mandatory. With this review, we intend to provide an up-to-date summary of the genetic conditions associated with overgrowth to emphasize a practical diagnostic approach of patients with tall stature and to discuss the limitations of current growth interruption treatment options.

show abstract

Section: Treatmentmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Diagnostic and therapeutic approach of tall stature

Albuquerque

Scalco

Jorge

2017

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…It has been reported that a nocturnal infusion of octreotide, a somatostatin analogue (201–995), reduces GH secretion and height prediction in tall children [ 42 , 43 ]. However, a more recent study, showed that long-term treatment with analogue of somatostatin (201–995) does not reduce final height in a manner sufficient to justify the treatment in tall stature [ 44 ].…”

Section: Introductionmentioning

confidence: 99%

Tall stature: a difficult diagnosis?

et al. 2017

View full text Add to dashboard Cite

Referral for an assessment of tall stature is less common than for short stature. Tall stature is defined as a height more than two standard deviations above the mean for age. The majority of subjects with tall stature show a familial tall stature or a constitutional advance of growth (CAG), which is a diagnosis of exclusion. After a careful physical evaluation, tall subjects may be divided into two groups: tall subjects with normal appearance and tall subjects with abnormal appearance. In the case of normal appearance, the paediatric endocrinologist will have to evaluate the growth rate. If it is normal for age and sex, the subject may be classified as having familial tall stature, CAG or obese subject, while if the growth rate is increased it is essential to evaluate pubertal status and thyroid status. Tall subjects with abnormal appearance and dysmorphisms can be classified into those with proportionate and disproportionate syndromes.A careful physical examination and an evaluation of growth pattern are required before starting further investigations. Physicians should always search for a pathological cause of tall stature, although the majority of children are healthy and they generally do not need treatment to cease growth progression.The most accepted and effective treatment for an excessive height prediction is inducing puberty early and leading to a complete fusion of the epiphyses and achievement of final height, using testosterone in males and oestrogens in females. Alternatively, the most common surgical procedure for reducing growth is bilateral percutaneous epiphysiodesis of the distal femur and proximal tibia and fibula.This review aims to provide up-to-date information and suggestions about the diagnosis and management of children with tall stature.

show abstract

“…Treatment of excessively tall stature with high doses of sex steroids is a well-known, though controversial, therapy [1,2,3,4,5,6,7]. In boys, high doses of testosterone are used to reduce final height.…”

Section: Introductionmentioning

confidence: 99%

“…To our knowledge, there are no studies comparing the effects of two different doses of testosterone on final height in tall boys [3,4]. Therefore, we compared the effects of 250 versus 500 mg testosterone enanthate every 2 weeks on near final height in boys with constitutional tall stature.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Tall Stature in Boys: Comparison of Two Different Treatment Regimens

Reinehr

Gueldensupp²,

Wünsch³

et al. 2011

Horm Res Paediatr

View full text Add to dashboard Cite

Background: High-dose testosterone treatment is a well-known, though still controversial, therapy in boys with tall stature. Methods: 161 boys with constitutional tall stature were treated at two different treatment centers (center A 114 patients; center B 47 patients). In center A, boys were treated with 500 mg and in center B with 250 mg testosterone enanthate intramuscularly every 2 weeks. Predicted adult height (PAH) was calculated according to the Bayley/Pinneau method using the Greulich-Pyle method for bone age determination. Results:At onset of treatment, the patients at the two centers did not differ with respect to chronological age (center A 14.2 ± 1.3 years; center B 13.5 ± 1.1 years), height (center A 187.8 ± 7.3 cm; center B 185.5 ± 5.5 cm), bone age (center A 13.8 ± 0.8 years; center B 13.6 ± 0.7 years), or PAH (center A 205.2 ± 5.2 cm; center B 204.8 ± 5.5 cm). Mean treatment duration was significantly longer in center A than in center B (14.2 ± 4.0 vs. 11.3 ± 2.2 months). At the end of the testosterone treatment, PAH did not differ significantly (center A 197.7 ± 5.3 cm; center B 196.1 ± 4.7 cm). The mean reduction in PAH at the end of treatment was 7.6 ± 5.0 cm (center A) and 8.7 ± 5.6 cm (center B) which is ∼50% of the expected growth at onset of treatment. Conclusions: A testosterone enanthate dose of 250 mg every 2 weeks was as effective in reducing adult height in boys with tall stature as a dose of 500 mg every 2 weeks.

show abstract

Treatment of tall stature in boys with somatostatin analogue 201–995: effect on final height

Cited by 19 publications

References 20 publications

MANAGEMENT OF ENDOCRINE DISEASE: Diagnostic and therapeutic approach of tall stature

MANAGEMENT OF ENDOCRINE DISEASE: Diagnostic and therapeutic approach of tall stature

Tall stature: a difficult diagnosis?

Treatment of Tall Stature in Boys: Comparison of Two Different Treatment Regimens

Contact Info

Product

Resources

About